All Congress Publications
Boehringer Ingelheim is committed to sharing knowledge with the healthcare community. Follow the links and find a variety of downloadable resources and articles with information related to Oncology.
41 - 50 of 102 results
Publications
Gathering our presentations, posters, abstracts, and publications, this educational resource offers materials across topics of interest in oncology. Explore the current topics below and revisit regularly to access the latest materials.
Poster
Phase I, first-in-human trial evaluating the STING agonist BI 1387446 alone and in combination with ezabenlimab in solid tumors
Author(s): Calvo et al.
Open-label, Phase I dose escalation/expansion trial of the anti-SIRPα monoclonal antibody BI 770371 in patients with advanced solid tumours, alone or in combination with the anti-PD-1 monoclonal antibody ezabenlimab
Author(s): Gutierrez et al.
![Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3](/events/inoncology-congresses/sites/default/files/2025-08/phase-1-bi-764532-dll3-dose-escalation.png)
Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T-cell engager) + ezabenlimab (anti-PD-1 antibody) in patients with small cell lung cancer and other neuroendocrine carcinomas expressing DLL3
Author(s): Mazières et al.
Beamion™ LUNG-1, an ongoing Phase Ia/Ib trial of the HER2 TKI, zongertinib (BI 1810631) in patients with advanced solid tumours with HER2 aberrations: latest data
Author(s): Ruiter et al.
Assessing the replicative potential of the oncolytic virus VSV-GP in patient-derived tumor biopsies ex vivo
Author(s): Schoeps et al.
An ongoing Phase I trial of the DLL3/CD3 IgG-like T-cell engager, BI 764532, in patients with DLL3-positive extrapulmonary neuroendocrine carcinomas
Author(s): Gambardella et al.
Phase I Beamion™ LUNG-1 trial of BI 1810631, a HER2 tyrosine kinase inhibitor, as monotherapy in patients with advanced/metastatic solid tumors with HER2 aberrations: updated data
Author(s): Heymach et al.
Predictive response biomarkers from Phase I clinical trial of SIRPalpha inhibitor, BI 765063, stand-alone and in combination with ezabenlimab, a PD-1 inhibitor, in patients with advanced solid tumors
Author(s): Champiat et al.
Updated data from the Phase I Beamion™ LUNG-1 trial of the HER2 tyrosine kinase inhibitor, BI 1810631, as monotherapy in patients with advanced/metastatic solid tumors with HER2 aberrations
Author(s): Heymach et al.
Presentation
Zongertinib in Asian patients with previously treated advanced HER2-mutant NSCLC
Author(s): Wu et al.